ESC 365 - Use of guideline directed medical therapy and clinical outcomes in cancer patients with de novo heart failure

Open Access

Use of guideline directed medical therapy and clinical outcomes in cancer patients with de novo heart failure

Session: Cardio-oncology - diagnostic and therapeutic advances

Topic: Cardio-Oncology

Speaker: Doctor Y. Sener (Rotterdam, NL)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Yusuf Ziya Sener

Erasmus University Rotterdam, Rotterdam (Netherlands (The))

1 presentation

0 follower

6 more presentations in this session

GLP1-RA associated with PCSK9i as new therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences

Speaker: Doctor N. Maurea (Naples, IT)

The GLP1RA Semaglutide exerts significant cardioprotective properties against anthracycline+/-trastuzumab induced cardiotoxicity: biochemical evidences

Speaker: Doctor N. Maurea (Naples, IT)

Detecting global cardiac involvement in breast cancer: the GAVS index

Speaker: Doctor C. Madaudo (Palermo, IT)

Echocardiographic indices of right ventricular function to predict cardiovascular outcomes in asian patients with cardiac amyloidosis

Speaker: Doctor N. Sari (Jakarta, ID)

Late cardiovascular toxicity in childhood cancer survivors from india: a cohort study.

Speaker: Professor R. Seth (Delhi, IN)

Access the full session

Cardio-oncology - diagnostic and therapeutic advances

Speakers: Doctor Y. Sener, Doctor N. Maurea, Doctor N. Maurea, Doctor C. Madaudo, Doctor N. Sari...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources